Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $558.41, for a total transaction of $5,304,895.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,622,864.33. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Trading Up 1.1%

NASDAQ:UTHR traded up $6.05 on Tuesday, reaching $565.70. 726,424 shares of the stock traded hands, compared to its average volume of 499,973. The company has a market capitalization of $24.79 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $607.89. The company’s fifty day simple moving average is $508.43 and its 200 day simple moving average is $480.83.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $6.19 EPS. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on UTHR shares. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, TD Cowen lifted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a report on Monday, March 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $586.00.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.